IL273719A - Improved methods of cell culture for adoptive cell therapy - Google Patents

Improved methods of cell culture for adoptive cell therapy

Info

Publication number
IL273719A
IL273719A IL273719A IL27371920A IL273719A IL 273719 A IL273719 A IL 273719A IL 273719 A IL273719 A IL 273719A IL 27371920 A IL27371920 A IL 27371920A IL 273719 A IL273719 A IL 273719A
Authority
IL
Israel
Prior art keywords
improved methods
cell culture
adoptive
cell
therapy
Prior art date
Application number
IL273719A
Other languages
Hebrew (he)
Other versions
IL273719B (en
Original Assignee
Wilson Wolf Mfg Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/493,768 external-priority patent/US20130115617A1/en
Application filed by Wilson Wolf Mfg Corporation filed Critical Wilson Wolf Mfg Corporation
Publication of IL273719A publication Critical patent/IL273719A/en
Publication of IL273719B publication Critical patent/IL273719B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL273719A 2012-06-11 2020-03-31 Improved methods of cell culture for adoptive cell therapy IL273719B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/493,768 US20130115617A1 (en) 2009-12-08 2012-06-11 Methods of cell culture for adoptive cell therapy
PCT/US2013/045209 WO2013188427A1 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy

Publications (2)

Publication Number Publication Date
IL273719A true IL273719A (en) 2020-05-31
IL273719B IL273719B (en) 2022-01-01

Family

ID=49758673

Family Applications (4)

Application Number Title Priority Date Filing Date
IL302514A IL302514A (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL288241A IL288241B2 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL235739A IL235739B (en) 2012-06-11 2014-11-17 Improved methods of cell culture for adoptive cell therapy
IL273719A IL273719B (en) 2012-06-11 2020-03-31 Improved methods of cell culture for adoptive cell therapy

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL302514A IL302514A (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL288241A IL288241B2 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
IL235739A IL235739B (en) 2012-06-11 2014-11-17 Improved methods of cell culture for adoptive cell therapy

Country Status (8)

Country Link
EP (1) EP2859093A4 (en)
JP (4) JP2015519080A (en)
CN (2) CN104411819B (en)
AU (3) AU2013274416B2 (en)
CA (1) CA2873608A1 (en)
IL (4) IL302514A (en)
SG (2) SG10201610387QA (en)
WO (1) WO2013188427A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
IL302514A (en) * 2012-06-11 2023-07-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
ES2980788T3 (en) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Center And Res Institute Inc Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN106795497A (en) * 2014-08-12 2017-05-31 人类起源公司 It is engineered to go back to the nest to the CAR T lymphocytes of lymph node B cells area, skin or intestines and stomach
CN106755023A (en) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 Chimeric antigen receptor immunocyte with safety switch and preparation method and application
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
NZ750005A (en) 2016-07-07 2023-06-30 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
CN106119193B (en) * 2016-07-28 2019-10-29 上海闪锦生物科技有限公司 A kind of preparation method for the T cells with antigenic specificity having NK cell speciality concurrently
IL266209B1 (en) 2016-10-26 2024-10-01 Iovance Biotherapeutics Inc Restimulation of cryopreserved tumor infiltrating lymphocytes
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
MX2019005617A (en) 2016-11-17 2019-08-14 Iovance Biotherapeutics Inc Remnant tumor infiltrating lymphocytes and methods of preparing and using the same.
EP3565586A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
TW201919662A (en) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
CR20200251A (en) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
JP2021503885A (en) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
CA3085765A1 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EA202092319A1 (en) 2018-03-29 2021-03-04 Айовэнс Байотерапьютикс, Инк. METHODS FOR OBTAINING TUMOR-INFILTING LYMPHOCYTES AND USING THEM IN IMMUNOTHERAPY
SG11202010319RA (en) 2018-04-27 2020-11-27 Iovance Biotherapeutics Inc Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039829A (en) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 Selection of improved tumor reactive t-cells
JP2022512899A (en) 2018-11-05 2022-02-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients refractory to anti-PD-1 antibody
MX2021005216A (en) 2018-11-05 2021-06-18 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy.
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
JP2024500403A (en) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer with tumor-infiltrating lymphocytes
JP2023554395A (en) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
TW202327631A (en) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AR127482A1 (en) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2004104185A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
PT2327763T (en) * 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Generation of antigen specific t cells
JP2009213462A (en) * 2008-02-15 2009-09-24 Kist-Europe Forschungs Gmbh Cell modification method and cell modification device
WO2011028531A1 (en) * 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US20130115617A1 (en) * 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
EP2698430A3 (en) * 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
DK2694640T3 (en) * 2011-04-08 2017-11-20 Baylor College Medicine REVERSION OF THE EFFECTS OF TUMOR MICRO-ENVIRONMENT USING CHEMICAL CYTOKIN RECEPTORS
EP2753351B1 (en) * 2011-09-08 2017-06-21 Yeda Research and Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013088114A1 (en) * 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
PL2812431T3 (en) * 2012-02-09 2020-02-28 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
CN102719399A (en) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 In vitro amplification method of self-specific T cell, prepared T cell system, pharmaceutical use of cell system and component monitoring method of cell system
SG10202111564SA (en) * 2012-05-18 2021-12-30 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
IL302514A (en) * 2012-06-11 2023-07-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
CA2924668A1 (en) * 2013-09-23 2015-03-26 Wilson Wolf Manufacturing Corporation Improved methods of genetically modifying animal cells
EP3515461A1 (en) * 2016-09-23 2019-07-31 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory t cells
EP3516043A1 (en) * 2016-09-26 2019-07-31 Tessa Therapeutics Pte. Ltd. T cell expansion method
EP3652306A1 (en) * 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
KR20220051348A (en) * 2019-07-29 2022-04-26 베이롤 칼리지 오브 메드신 Antigen-specific T cell banks and methods of making and therapeutic use thereof
EP4013897A4 (en) * 2019-08-16 2024-07-24 Baylor College Medicine Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis
US20210371822A1 (en) * 2020-05-27 2021-12-02 University Of Southern California Methods for expanding sars-cov2-antigen-specific t cells, compositions and uses related thereto

Also Published As

Publication number Publication date
IL273719B (en) 2022-01-01
CA2873608A1 (en) 2013-12-19
SG11201407819UA (en) 2014-12-30
CN110241086A (en) 2019-09-17
IL235739B (en) 2020-04-30
EP2859093A1 (en) 2015-04-15
IL235739A0 (en) 2015-01-29
JP2023065668A (en) 2023-05-12
WO2013188427A1 (en) 2013-12-19
AU2019240684A1 (en) 2019-10-24
IL302514A (en) 2023-07-01
IL288241B2 (en) 2023-10-01
JP2020174685A (en) 2020-10-29
SG10201610387QA (en) 2017-02-27
AU2013274416A1 (en) 2015-01-15
CN104411819B (en) 2019-05-10
EP2859093A4 (en) 2016-08-17
JP2015519080A (en) 2015-07-09
IL288241A (en) 2022-01-01
IL288241B1 (en) 2023-06-01
JP2018138059A (en) 2018-09-06
JP7244461B2 (en) 2023-03-22
AU2022202172A1 (en) 2022-04-21
AU2013274416B2 (en) 2019-07-04
CN104411819A (en) 2015-03-11

Similar Documents

Publication Publication Date Title
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
HK1210494A1 (en) Devices and methods for culture of cells
HK1199905A1 (en) Culturing of mesenchymal stem cells
IL220232A0 (en) Improved methods of cell culture for adoptive cell therapy
IL236672B (en) System and methods for preparation of adipose-derived stem cells
EP2861612A4 (en) Methods of preparing pluripotent stem cells
EP2968549A4 (en) Methods of cell culture
EP2971040A4 (en) Methods of cell culture
EP2971014A4 (en) Methods of cell culture
SI2683815T1 (en) Genetically modified cell and process for use of said cell
SG11201503579RA (en) Cell culture med
GB201100180D0 (en) Tumour cell and tissue culture
HK1208727A1 (en) Tumor cell isolation purification process and methods for use thereof
SG10201700670WA (en) Cell culture
EP2860239A4 (en) Vessel for culturing human es cells
GB2520899B (en) Method for discriminating differentiation degree of pluripotent stem cell
GB201211873D0 (en) Cell culture